TurnerTrends Stock Rating Report for BMRN
Data valid for week beginning July 14, 2008
|
BMRN [News]
|
BioMarin Pharmaceutical Inc
|
Company Profile
"BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI- Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU)- and Aldurazyme (laronidase) that is used for the treatment of mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase. The company also develops various product candidates for the treatment of genetic diseases, which include PEG-PAL, a preclinical enzyme substitution therapy for the treatment of severe PKU- PEG-PAL for phenylketonurics, which are not BH4-responsive- and BH4 for the treatment of various other indications, including cardiovascular indications. In addition, it conducts preclinical development of various other enzyme product candidates for genetic and other diseases, as well as an immune tolerance platform technology to overcome limitations associated with the delivery of protein-based pharmaceuticals. Further, the company holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. BioMarin Pharmaceutical sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Canada, Japan, and the European Union. It has a strategic alliance with Merck Serono S.A.- collaboration with IGAN Biosciences- and joint venture with Genzyme Corporation. The company was founded in 1996 and is headquartered in Novato, California."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Thu, 17 Jul 2008 15:50:00 Etc/GMT | Trading Biotech With ETFs (at Minyanville.com) | | Thu, 17 Jul 2008 10:23:56 Etc/GMT | Coverage initiated on Biomarin Pharm by Oppenheimer (Briefing.com) | | Wed, 16 Jul 2008 20:06:34 Etc/GMT | A Big Upgrade for Celgene (at Motley Fool) | | Wed, 16 Jul 2008 20:00:00 Etc/GMT | Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU (PR Newswire) | | Wed, 16 Jul 2008 19:45:27 Etc/GMT | Big Biotech Booms But IBB Falls Flat (at Seeking Alpha) | | Wed, 16 Jul 2008 19:40:45 Etc/GMT | A Big Move From ViroPharma (at Motley Fool) | | Tue, 15 Jul 2008 16:10:46 Etc/GMT | BioMarin Pharmaceutical Inc. Earnings Call scheduled for Tue, Aug 5 (CCBN) | | Tue, 15 Jul 2008 13:00:00 Etc/GMT | BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET) (PR Newswire) | | Mon, 7 Jul 2008 14:36:56 Etc/GMT | Biotech Stocks: Second-Half '08 Preview (at TheStreet.com) | | Sat, 5 Jul 2008 12:00:17 Etc/GMT | Is Your House Dooming Your Retirement? (at Motley Fool) | | Tue, 1 Jul 2008 13:00:00 Etc/GMT | BioMarin to Present at the Collins Stewart Growth Conference (PR Newswire) | | Mon, 30 Jun 2008 16:34:36 Etc/GMT | Russell 1000 adds 5 health care stocks (AP) | | Thu, 26 Jun 2008 12:55:29 Etc/GMT | BioMarin, Myriad, and Regeneron Show a Quiet Strength (at Seeking Alpha) | | Tue, 24 Jun 2008 17:26:21 Etc/GMT | BioMarin Selloff Offers a Buy: Analysts (at TheStreet.com) | | Tue, 24 Jun 2008 00:35:38 Etc/GMT | 'Lost' Patients Whack BioMarin Shares (at TheStreet.com) | | Fri, 20 Jun 2008 21:52:27 Etc/GMT | Five Companies That Love (Earnings) Surprises (at Investopedia) | | Thu, 19 Jun 2008 20:02:29 Etc/GMT | Live From Bio: Investing in Orphan Drugs (at Motley Fool) | | Tue, 17 Jun 2008 20:20:00 Etc/GMT | Big Energy Dip Triggers Buys (at Forbes.com) | | Mon, 16 Jun 2008 17:07:00 Etc/GMT | TradingMarkets Monday Stock Movers (TradingMarkets.com) | | Thu, 12 Jun 2008 20:31:53 Etc/GMT | Health Winners & Losers: Invitrogen (at TheStreet.com) | News provided by Yahoo! Finance |
|
